5th study arm in 12-week Phase 1b Study receives lead clinical site approval  Kelowna, British Columbia – February 24, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces it has received lead clinical site human research ethics committee (“HREC”) approval that was required before dosing can begin in the 5th study arm of the Company’s Phase 1b, 12-week chronic study GLP-1-H24-4, (the “Study ...